Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Dependable recurring dividends from quality, high-yield stocks like these five are a recipe for passive income success.

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...

The stock market saw something incredible in 2024, with the “Magnificent 7” tech giants leading the charge and driving a huge ...

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Schwab U.S. Dividend Equity ETF is a clear buy with a look at its top 10 holdings. Click here to why I rate SCHD a Buy.

MitoRx Therapeutics strengthens its leadership with the appointments of Lubor Gaal as chief business officer and Stacey ...

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...